Lopez-Berestein and his colleagues worked with liposomal ASOs targeting Grb2 (BP1001, Prexigebersen) and Bcl-2 oncogenes for breast cancer and leukemia cells, respectively [123]. Here, GRB2 is linked to breast carcinoma.